Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open‐angle glaucoma: a pilot study

Desai, Rajen U.; Singh, Kuldev; Lin, Shan

doi:10.1111/j.1442-9071.2012.02836.x

Cited by 14 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three studies included only participants with neovascular glaucoma (Arcieri 2015; Mahdy 2013; Teixeira 2012), while the remainder of studies included a combination of glaucoma subtypes. The smallest trial enrolled 11 participants (Desai 2013), and the largest trial enrolled 276 participants (ABC 2011). …”

Section: Resultsmentioning

confidence: 99%

“…Two trials compared early aqueous suppression versus a standard medication regimen for postoperative increases in IOP (Law 2016; Pakravan 2014). Four trials evaluated an anti-vascular endothelial growth factor (VEGF) agent, with one trial using ranibizumab, Desai 2013, and three trials using bevacizumab (Arcieri 2015; Mahdy 2013; Rojo-Arnao 2011). Two trials evaluated a corticosteroid, with one trial comparing intravitreal triamcinolone versus none (Teixeira 2012), and another trial comparing topical dexamethasone versus topical ketorolac (Yuen 2011).…”

Section: Resultsmentioning

confidence: 99%

“…The average number of postoperative glaucoma medications was reported in all except five trials (Desai 2013; Gerber 1997; Gil-Carrasco 2016; Kee 2001; Mahdy 2013). …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…Compared with cohorts in prospective studies comparing AGV with BGI, our cohort had slightly lower mean IOP (14.2 mmHg in the non-TA group and 14.7 mmHg in the TA group compared with 15.7 mmHg and 16.7 mmHg in the Ahmed Baerveldt Comparison Study3 and Ahmed Versus Baerveldt Study4 trials, respectively) on a similar average number of medications at 6 months. Prior studies using antimetabolites and antivascular endothelial growth factor agents as adjuncts to Ahmed valve implantation similarly found no difference in final outcomes with adjunctive treatment 19–22…”

Section: Discussionmentioning

confidence: 98%

Hypertensive phase and early complications after Ahmed glaucoma valve implantation with intraoperative subtenon triamcinolone acetonide

Turalba

Pasquale²

2014

OPTH

View full text Add to dashboard Cite

ObjectiveTo evaluate intraoperative subtenon triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma valve (AGV) implantation.DesignRetrospective comparative case series.ParticipantsForty-two consecutive cases of uncontrolled glaucoma undergoing AGV implantation: 19 eyes receiving intraoperative subtenon TA and 23 eyes that did not receive TA.MethodsA retrospective chart review was performed on consecutive pseudophakic adult patients with uncontrolled glaucoma undergoing AGV with and without intraoperative subtenon TA injection by a single surgeon. Clinical data were collected from 42 eyes and analyzed for the first 6 months after surgery.Main outcome measuresPrimary outcomes included intraocular pressure (IOP) and number of glaucoma medications prior to and after AGV implantation. The hypertensive phase (HP) was defined as an IOP measurement of greater than 21 mmHg (with or without medications) during the 6-month postoperative period that was not a result of tube obstruction, retraction, or malfunction. Postoperative complications and visual acuity were analyzed as secondary outcome measures.ResultsFive out of 19 (26%) TA cases and 12 out of 23 (52%) non-TA cases developed the HP (P=0.027). Mean IOP (14.2±4.6 in TA cases versus [vs] 14.7±5.0 mmHg in non-TA cases; P=0.78), and number of glaucoma medications needed (1.8±1.3 in TA cases vs 1.6±1.1 in the comparison group; P=0.65) were similar between both groups at 6 months. Although rates of serious complications did not differ between the groups (13% in the TA group vs 16% in the non-TA group), early tube erosion (n=1) and bacterial endophthalmitis (n=1) were noted with TA but not in the non-TA group.ConclusionsSubtenon TA injection during AGV implantation may decrease the occurrence of the HP but does not alter the ultimate IOP outcome and may pose increased risk of serious complications within the first 6 months of surgery.

show abstract

“…В рандомизированном контроли-руемом исследовании R. Desai троекратно вводил ранибизумаб пациентам с дренажем Ахмеда -за 9 дней до установки дренажа, через 1 и 2 меся-ца после операции. Успех был достигнут в 83 % случаев в группе ранибизумаба и 40 % в группе контроля [13].…”

Section: применение ингибиторов Vegf при неоваскулярной глаукомеunclassified

VEGF inhibitors in glaucoma surgery

Mamikonyan¹,

Petrov²,

Сафонова³

2016

Ophthalmology Reports

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a signaling protein, that controls vasculogenesis, angiogenesis, vascular support and stimulates permeability of small blood vessels. The following isoforms are presently known: VEGF-A, VEGF-B, VEGF-C, VEGF-В and PGF. VEGF-A, that regulates neoangiogenesis and fibroblast formation, is thought to play the most important role in human organism. Increased expression of VEGF may lead to development and aggravation of pathological conditions including oncology. The article presents a review of preclinical and clinical studies of the main VEGF-inhibitors - bevacizumab and ranibizumab, as well as a brief account on other existing medications of this group. It describes ophthalmological indications for the use of antiangiogenetic agents, as well as the ways of their possible off-label use. The review presents investigations of intravitreal and intracameral injections of VEGF-inhibitors in patients with retinal, chorioidal, iris, and anterior chamber angle neovascularization. It gives examples of successful anti-VEGF use before Ahmed glaucoma valve drainage device implantation and in cases of neovascular glaucoma, induced by radiation therapy for intraocular tumors. Tenon’s capsule’s fibroblasts take part in the process of postoperative wound healing and scarring. According to the latest research, this process could be modulated by angiogenesis inhibitors. This review also recounts the use of anti-angiogenic agents to inhibit postoperative fibroblast proliferation, when used as monotherapy, or as an adjuvant to mitomycin С or 5-fluorouracil. It reviews the research on VEGF-inibitors use in combination with postoperative needling.

show abstract

Intravitreal ranibizumab as an adjunct for Ahmed valve surgery in open‐angle glaucoma: a pilot study

Abstract: Background: To determine the safety and efficacy of intravitreal ranibizumab therapy before and after Ahmed tube insertion for open-angle glaucoma as a means of optimizing postoperative intraocular pressure control.

Cited by 14 publications

References 20 publications

Aqueous shunts for glaucoma

Aqueous shunts for glaucoma

Hypertensive phase and early complications after Ahmed glaucoma valve implantation with intraoperative subtenon triamcinolone acetonide

VEGF inhibitors in glaucoma surgery

Contact Info

Product

Resources

About